Company Bio-Rad Laboratories, Inc.
Stocks
BIO
US0905722072
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 285.94 USD | -2.22% |
|
-2.85% | -5.63% |
Business description: Bio-Rad Laboratories, Inc.
Number of employees: 7,450
Sales by Activity: Bio-Rad Laboratories, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Clinical Diagnostics | 1.52B | 1.45B | 1.49B | 1.54B | 1.56B |
Life Science | 1.4B | 1.35B | 1.18B | 1.03B | 1.02B |
Other Operations | 5.8M | 4M | 3.6M | 500K | - |
Geographical breakdown of sales: Bio-Rad Laboratories, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 1.13B | 1.16B | 1.12B | 1.04B | 1.02B |
Europe | 947M | 852M | 820M | 834M | 882M |
Asia | 688M | 639M | 563M | 522M | 513M |
Other (primarily Canada and Latin America) | 157M | 155M | 167M | 169M | 165M |
Executive Committee: Bio-Rad Laboratories, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 76 | 01/01/2003 |
| President | 61 | 09/09/2024 | |
Roop Lakkaraju
DFI | Director of Finance/CFO | 55 | 15/04/2024 |
Allison Schwartz
PRN | Corporate Officer/Principal | 45 | 01/01/2016 |
Edward Chung
IRC | Investor Relations Contact | - | 01/06/2021 |
Composition of the Board of Directors: Bio-Rad Laboratories, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CHM | Chairman | 76 | 01/01/2012 |
Jeffrey Edwards
BRD | Director/Board Member | 65 | 25/04/2017 |
Gregory Hinckley
BRD | Director/Board Member | 79 | 25/04/2017 |
| Director/Board Member | 68 | 25/04/2017 | |
Arnold Pinkston
BRD | Director/Board Member | 67 | 25/04/2017 |
Allison Schwartz
BRD | Director/Board Member | 45 | 01/07/2021 |
Holdings: Bio-Rad Laboratories, Inc.
| Name | Stocks | % | Valuation |
|---|---|---|---|
SARTORIUS AG 25.61% | 9,588,908 | 25.61% | 2 743 M $ |
| 3,203,098 | 11.19% | 20 M $ |
Company details: Bio-Rad Laboratories, Inc.
Group companies: Bio-Rad Laboratories, Inc.
| Name | Category and Sector |
|---|---|
Bio-Rad Laboratories MEPE | |
Bio-Rad Laboratories MEPE | |
Bio-Rad Laboratories GmbH
 Bio-Rad Laboratories GmbH Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Other Medical Equipment, Supplies & Distribution
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.22% | -2.85% | +23.03% | -23.93% | 7.89B | |
| -1.64% | -3.17% | -35.38% | -13.04% | 156B | |
| -0.16% | -1.80% | -9.37% | -4.84% | 103B | |
| +0.07% | +2.41% | -4.53% | +57.08% | 54.77B | |
| +3.00% | -0.04% | +54.23% | +54.37% | 53.52B | |
| -0.75% | -3.25% | -16.18% | -41.67% | 40.6B | |
| -1.40% | +8.93% | - | - | 31.4B | |
| +0.16% | +3.44% | -9.03% | -40.61% | 29.04B | |
| -0.46% | +4.55% | +46.20% | -7.99% | 23.34B | |
| -2.85% | -3.36% | -17.02% | -0.74% | 20.81B | |
| Average | -0.73% | +0.97% | +3.55% | -2.38% | 52.06B | |
| Weighted average by Cap. | -0.62% | +0.31% | -7.87% | +0.49% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIO Stock
- Company Bio-Rad Laboratories, Inc.
Select your edition
All financial news and data tailored to specific country editions
